Hyloris Pharmaceuticals Past Performance
Past criteria checks 0/6
Hyloris Pharmaceuticals's earnings have been declining at an average annual rate of -15.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 63.6% per year.
Key information
-15.9%
Earnings growth rate
4.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.3% |
| Revenue growth rate | 63.6% |
| Return on equity | -25.6% |
| Net Margin | -404.9% |
| Next Earnings Update | 14 Mar 2024 |
Recent past performance updates
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 3 | -12 | 5 | 12 |
| 31 Mar 23 | 3 | -12 | 4 | 11 |
| 31 Dec 22 | 3 | -11 | 4 | 10 |
| 30 Sep 22 | 3 | -10 | 3 | 9 |
| 30 Jun 22 | 3 | -8 | 3 | 8 |
| 31 Mar 22 | 3 | -10 | 3 | 7 |
| 31 Dec 21 | 3 | -12 | 3 | 5 |
| 30 Sep 21 | 2 | -12 | 2 | 4 |
| 30 Jun 21 | 1 | -12 | 1 | 3 |
| 31 Mar 21 | 1 | -10 | 2 | 3 |
| 31 Dec 20 | 0 | -7 | 2 | 3 |
| 30 Sep 20 | 0 | -8 | 3 | 2 |
| 30 Jun 20 | 0 | -8 | 3 | 2 |
| 31 Mar 20 | 0 | -6 | 1 | 2 |
| 31 Dec 19 | 0 | -5 | 1 | 1 |
| 31 Dec 18 | 0 | -6 | 1 | 5 |
| 31 Dec 17 | 0 | -4 | 2 | 2 |
Quality Earnings: HYL is currently unprofitable.
Growing Profit Margin: HYL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HYL is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare HYL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HYL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: HYL has a negative Return on Equity (-25.58%), as it is currently unprofitable.